Clinical trials: Lipids Metabolism
Type II Hyperlipidemia
A Safety and Efficacy Study of DRL-17822, a Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Patients With Abnormal Cholesterol Levels
The purpose of this study is to determine if a new drug, DRL-17822, is safe and effective in elevating high density lipoprotein cholesterol (HDL-C) and reducing low density lipoprotein cholesterol (LDL-C) in people with abnormal…
- Trial name
- NCT01388816
- Where
- 12 sites in Italy, Poland and 1 more
- Volunteers
- 176 people
- Sponsor
- Dr. Reddy's Laboratories Limited
Familial Chylomicronemia Syndrome
Olezarsen Early Access Program for Patients With Familial Chylomicronemia Syndrome (FCS)
The purpose of the Expanded Access Program is to provide pre-approval access of olezarsen to eligible patients with Familial Chylomicronemia Syndrome (FCS).
- Trial name
- NCT06360237
- Testing
- Olezarsen
- Where
- United States
- Sponsor
- Ionis Pharmaceuticals, Inc.
Hypertension, Metabolic Syndrome
Effect of Valsartan on Lipid Subfractions in Hypertensive Patients With Metabolic Syndrome
The purpose of this study is to evaluate potential effects of valsartan on lipid subfractions and other parameters in lipid metabolism in patients with essential hypertension and metabolic syndrome.
- Trial name
- NCT00394745
- Testing
- Valsartan
- Where
- 2 sites in Germany, Switzerland
- Volunteers
- 45 people
- Sponsor
- Novartis
Dyslipidemia
Evaluation of a Flushing ASsessment Tool (FAST) in Subjects Receiving Niacin Extended-release Plus Aspirin
The primary purpose of this study was to evaluate the psychometric characteristics (reliability, validity, and responsiveness) of a Flushing ASsessment Tool (FAST) in subjects receiving niacin extended-release (NER) plus aspirin…
- Trial name
- NCT00630877
- Testing
- Niacin extended-release (NER), Aspirin (ASA)
- Where
- 40 sites in United States
- Volunteers
- 276 people
- Sponsor
- Abbott
Type 2 Diabetes Mellitus
Colesevelam for Children With Type 2 Diabetes
This study will evaluate the efficacy and safety of the study drug in treating type 2 diabetes in children 10 to 17 years old. The groups will be low-dose (0.625 g Welchol) and high-dose (3.75 g Welchol).
- Trial name
- WELKid DM (NCT01258075)
- Testing
- High-dose colesevelam, Low-dose colesevelam
- Where
- 24 sites in United States
- Volunteers
- 236 people
- Sponsor
- Daiichi Sankyo
Gaucher Disease
Plant Cell Expressed Recombinant Human Glucocerebrosidase Extension Trial
Gaucher disease, the most prevalent lysosomal storage disorder, is caused by mutations in the human glucocerebrosidase gene (GCD) leading to reduced activity of the lysosomal enzyme glucocerebrosidase and thereby to the…
- Trial name
- NCT00705939
- Testing
- Taliglucerase alfa
- Where
- 11 sites in United States, Australia and 6 more
- Volunteers
- 45 people
- Sponsor
- Pfizer
ASCVD, Elevated Cholesterol
Inclisiran for Participants With Atherosclerotic Cardiovascular Disease and Elevated Low-density Lipoprotein Cholesterol
This is a Phase III, placebo-controlled, double-blind, randomized study in participants with ASCVD and elevated LDL-C despite maximum tolerated dose of LDL-C lowering therapies to evaluate the efficacy, safety, and tolerability…
- Trial name
- ORION-10 (NCT03399370)
- Testing
- Inclisiran Sodium
- Where
- 145 sites in United States
- Volunteers
- 1,561 people
- Sponsor
- The Medicines Company
Gaucher Disease, Type 1
A Gene Therapy Study in Patients With Gaucher Disease Type 1
This study is a first-in-human, open-label, safety, tolerability, and efficacy study in adult patients with Gaucher disease Type 1.
- Trial name
- GALILEO-1 (NCT05324943)
- Testing
- FLT201
- Where
- 10 sites in United States, Brazil and 4 more
- Volunteers
- 10 people
- Sponsor
- Spur Therapeutics
Hypertension and Dyslipidemia
A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(5) 80/20/10mg
A Clinical Trial to evaluate the Pharmacokinetics and Tolerability of CKD-386(5)
- Trial name
- NCT05698043
- Testing
- CKD-386(5), D013, D326, D337
- Where
- South Korea
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Hypercholesterolemia
Ascending Multi-dose Study of REGN727(SAR236553) With and Without Concomitant Atorvastatin
This study will test the safety, tolerability, and bioeffects (how the body reacts to the drug) of REGN727 compared with placebo (an inactive substance that contains no medicine) in hyperlipidemic patients with or without…
- Trial name
- NCT01161082
- Testing
- REGN727(SAR236553)
- Where
- 2 sites in United States
- Volunteers
- 72 people
- Sponsor
- Regeneron Pharmaceuticals
Hypercholesterolemia
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD8233 in Healthy Male Subjects With Increased Elevated LDL-C Levels.
AZD8233 has not been evaluated in clinical studies previously. This is a first-in-human (FiH) study. This study will assess the safety, tolerability and pharmacokinetics (PK) of AZD8233, following subcutaneous (SC) administration…
- Trial name
- NCT03593785
- Testing
- AZD8233
- Where
- United States
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Fabry Disease
A Study of Renal Function in Treatment-naïve, Young Male Patients With Fabry Disease
No investigational drug will be administered in this study for the treatment of Fabry disease. This will be a multicenter, multinational, non-treatment, cross-sectional study of young male patients with Fabry disease who have not…
- Trial name
- NCT01839526
- Testing
- Iohexol
- Where
- 22 sites in United States, Argentina and 12 more
- Volunteers
- 39 people
- Sponsor
- Genzyme, a Sanofi Company
Diabetes, Hyperlipidemia
Diabetic Under 70 (Diabetics Below 70)
A screening project of diabetics with a very high cardiovascular risk (e.g. diabetes plus coronary heart disease) who already receive cholesterol-lowering therapy.
- Conditions
- Diabetes, Hyperlipidemia, Atherosclerosis
- Trial name
- NCT00516204
- Where
- Austria
- Volunteers
- 685 people
- Sponsor
- AstraZeneca
Hypercholesterolemia
Bioequivalence Study Of Pediatric Appropriate Formulation
To determine bioequivalence of pediatric appropriate 80 mg atorvastatin formulation comparing to the 80 mg commercial atorvastatin calcium tablet formulation.
- Trial name
- NCT00758004
- Testing
- Atorvastatin, Atorvastatin pediatric appropriate formulation
- Where
- United States
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Dyslipidemia
A Study of AZD8233 in Participants With Dyslipidemia.
A Phase 1 and 2 Study of AZD8233 in Participants with Dyslipidemia and this study consists of Part A , Part B and Part C. Part A is designed as a randomized, single-blind (blinding of participants and sites), placebo-controlled…
- Trial name
- HAYATE (NCT04823611)
- Testing
- Part A:AZD8233, Part B:AZD8233
- Where
- 7 sites in Japan
- Volunteers
- 87 people
- Sponsor
- AstraZeneca
Diabetes Mellitus
Efficacy of Pioglitazone on Macrovascular Outcome in Patients With Type 2 Diabetes
The purpose of this study is to determine whether pioglitazone, once daily (QD), can delay the time to death, heart attack, acute coronary syndrome, heart bypass surgery, stroke, leg bypass surgery or amputation in patients with…
- Trial name
- PROactive (NCT00174993)
- Testing
- Pioglitazone
- Where
- 19 sites in Austria, Belgium and 17 more
- Volunteers
- 4,373 people
- Sponsor
- Takeda
Hypercholesterolemia, Hypertension
Evaluating the Efficacy and Safety of Co-administrated Rosuvastatin/Ezetimibe and Telmisartan/Amlodipine
The purpose of this study is to evaluate the efficacy and safety of co-administrated Rosuvastatin/Ezetimibe and Telmisartan/Amlodipine in patients with primary hypercholesterolemia and essential hypertension.
- Trial name
- NCT04158076
- Testing
- Ezetimibe/Rosuvastatin, Telmisartan, Telmisartan/Amlodipine 80 Mg-5 Mg ORAL TABLET
- Where
- South Korea
- Volunteers
- 131 people
- Sponsor
- Addpharma Inc.
Hypercholesterolemia
Efficacy of Lapaquistat Acetate and Atorvastatin on Blood Cholesterol Levels in Subjects With Primary Hypercholesterolemia
The purpose of this study is to determine the efficacy of lapaquistat acetate, once daily (QD), on lowering cholesterol in subjects already taking atorvastatin.
- Trial name
- NCT00143676
- Testing
- Lapaquistat acetate and atorvastatin, Atorvastatin
- Where
- 78 sites in United States
- Volunteers
- 448 people
- Sponsor
- Takeda
Hypercholesteremia
A Study Measuring Effects on Intima Media Thickness: An Evaluation of Rosuvastatin 40 mg (METEOR)
The purpose of this trial is to see if rosuvastatin will be effective in decreasing the thickness of the walls of the arteries in the neck for people who already have some evidence of thickening of these walls.
- Trial name
- NCT00225589
- Testing
- Rosuvastatin calcium
- Where
- 57 sites in United States, Belgium and 6 more
- Volunteers
- 840 people
- Sponsor
- AstraZeneca
Hypercholesterolemia, Coronary Disease
Investigational Drug Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-801)
This study will evaluate patients who have coronary heart disease to determine if an investigational drug will further lower cholesterol when taken in combination with an approved cholesterol lowering medication.
- Trial name
- NCT00092599
- Testing
- MK0653, ezetimibe
- Volunteers
- 410 people
- Sponsor
- Organon and Co
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.